AAX Biotech welcomes new CEO to drive advancements in next-generation antibody therapeutics
Biotech company AAX Biotech, specializing in innovative, patentable technologies for improving antibody-based medicines, is taking a significant step forward by appointing Maria Lisa Knudsen, PhD, as CEO. The appointment is expected to contribute to the company's growth and the development of its pioneering technologies.
AAX Biotech is a Swedish startup biotech company aiming to solve unmet needs in developing next-generation antibody therapeutics. The company’s two unique and patentable technologies, Seqitope™ and Opti-mAb™, improve the performance and developability of antibody-based therapeutics and offer a unique solution in a rapidly growing market.
AAX Biotech is pleased to announce that Maria Lisa Knudsen, PhD, has been appointed as CEO of the company. Maria Lisa Knudsen has a broad international experience in research and business development. Having obtained a PhD in Infection Biology from the prestigious Karolinska Institutet, she conducted extensive research at renowned institutions in the United States and Singapore. Subsequently, she made a transition to the role of Business Development Director at Salipro Biotech AB in Sweden, where she was involved in out-licensing the company’s technology platform for drug discovery as well as establishing an internal pipeline.
“We are thrilled to have Maria join the team as we strengthen our IP portfolio and build partnerships with biotech and pharma companies. Maria’s combined experience in antibody research and business development will be instrumental for advancing AAX Biotech’s cutting-edge technologies for antibody therapeutics,” says Daniel Johansson, co-founder and Chief Scientific Officer of AAX Biotech.
“I am honored to take the role of leading AAX Biotech. It is an exciting new company with unique technologies that have the potential to significantly accelerate the development of next-generation antibody drugs that address unmet medical needs, improving therapeutics and patient lives. I look forward to working with the innovative team at AAX Biotech and fulfilling our vision of becoming a distinguished and highly competitive partner serving the global biopharmaceutical industry in the next couple of years”, says Maria Lisa Knudsen, new CEO of AAX Biotech.
AAX Biotech aims to become a key player with a game-changing potential for next-generation antibody therapies such as bispecific antibodies and CAR-T cell treatments in the field of cancer care. The company is dedicated to advancing this promising area through cutting-edge technologies, with a focus on amplifying the development and efficacy of these innovative treatments.
For more information, please contact:
Maria Lisa Knudsen, CEO
+46 72 939 5018
maria.knudsen@aaxbiotech.com
About AAX Biotech AB
AAX Biotech AB is a biotech company specializing in next-generation antibody therapeutics. The company offers two unique and proprietary technologies, Seqitope™ and Opti-mAb™, that enable high throughput and high-resolution epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Both technologies aim to produce better and more effective antibody-based medicines. These innovations position AAX Biotech as a key player in the rapidly growing antibody therapeutics market. AAX Biotech is founded by experts from Karolinska Institutet in Stockholm, Sweden. Visit aaxbiotech.com to learn more and follow AAX Biotech on LinkedIn.
